selected scholarly activity
-
conferences
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).. Journal of Clinical Oncology. 2022
- Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.. Journal of Clinical Oncology. 269-269. 2022
- Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy). Radiotherapy and Oncology. S197-S197. 2021
- Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415.. Cancer Research. 2021
- Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS ONE. 2021
- Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415.. Journal of Clinical Oncology. 60-60. 2021
- Impact of Pelvic Intensity-modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. e250-e250. 2020
- Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP). International Journal of Radiation Oncology Biology Physics. S119-S120. 2020
- A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415. Journal of Clinical Oncology. 2020
- IMPACT OF PELVIC INTENSITY-MODULATED RADIOTHERAPY (IMRT) ON LYMPH NODE COVERAGE AND DOSE TO CRITICAL ORGANS, COMPARE TO THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT), IN LOCALIZED HIGH-RISK PROSTATE CANCER. Radiotherapy and Oncology. S68-S68. 2019
- NRG Oncology/RTOG 0415, hypofractionation in patients with low-risk prostate cancer: are patient reported outcomes the practice change tipping point?. Quality of Life Research. 38-39. 2017
- Randomized Study of Quality of Life in Patients with High-Risk Prostate Cancer Undergoing Radiotherapy: Role of Pelvic Nodal IMRT. International Journal of Radiation Oncology Biology Physics. E211-E212. 2017
- Investigation Into the Feasibility of Having Uniform Compliance Dosimetric Criteria Across Radiation Therapy Treatment Modalities for NRG Oncology/RTOG 0938 by Using Machine Learning. International Journal of Radiation Oncology Biology Physics. E230-E231. 2016
- NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results. International Journal of Radiation Oncology Biology Physics. S2-S3. 2016
- NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.. Journal of Clinical Oncology. 1-1. 2016
- Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).. Journal of Clinical Oncology. 27-27. 2016
- NRG Oncology RTOG 0415: A Randomized Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 3-4. 2016
- Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 2-2. 2016
- Global Radiation Oncology Elective in Teaching CanMEDS Competencies. International Journal of Radiation Oncology Biology Physics. E377-E377. 2015
- The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.. Journal of Clinical Oncology. 5523-5523. 2015
- Cardiac Sparing With Breath-hold Technique: A Dosimetric Evaluation of Benefits in Different Patient Populations. International Journal of Radiation Oncology Biology Physics. S257-S257. 2012
- Identifying Risk Factors for Locoregional Recurrence Following Postmastectomy Radiation Therapy. International Journal of Radiation Oncology Biology Physics. S251-S251. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 2012
- Electronic Web-based Technology Significantly Improves Quality of Life (QOL) Data Collection: Analysis of RTOG 0828. International Journal of Radiation Oncology Biology Physics. S111-S111. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 2011
- DELTA: A Randomized Trial of Decongestive Lymphatic Therapy for Women with Lymphedema following Treatment for Breast Cancer. International Journal of Radiation Oncology Biology Physics. S53-S53. 2009
- LDR Prostate Brachytherapy: Dosimetric Evaluation of Stabilizing Needles and Seminal Vesicle Implants. International Journal of Radiation Oncology Biology Physics. S353-S353. 2009
- Influence of Gold Seed Implantation on Defining Target Volumes for Conformal Radiotherapy of Prostate Cancer. International Journal of Radiation Oncology Biology Physics. S322-S322. 2008
- 183 Can an In Vitro Assay Predict Radiation Sensitivity in Patients with Carcinoma of the Prostate?. Radiotherapy and Oncology. S53-S53. 2006
- 14 Randomized Trial Comparing Iridium Plus External-Beam Radiation Therapy with External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Radiotherapy and Oncology. S5-S5. 2005
- 201 Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-CRT PLANS. Radiotherapy and Oncology. S59-S59. 2005
- Po‐Poster ‐ 29: Radiation‐induced apoptosis of lymphocytes to predict late toxicity from radiotherapy. Medical Physics. 2415-2415. 2005
- A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics. S448-S448. 2004
- Arm lymphedema in breast cancer patients: Is it always related to treatment. International Journal of Radiation Oncology Biology Physics. S402-S402. 2004
- Clinical screening for lymphedema in breast cancer patients: Validation of Canadian guidelines.. Radiotherapy and Oncology. S42-S42. 2004
- Lymphedema in breast cancer patients screened during the first year of a randomized trial: Is treatment always the cause?. Radiotherapy and Oncology. S42-S42. 2004
- Local tumor control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: A meta-analysis. Radiology. 599-599. 2002
-
journal articles
- Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.. Annals of Oncology. 36:572-582. 2025
- Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.. Prostate. 2025
- Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.. Journal of Clinical Oncology. 43. 2025
- PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.. Journal of Clinical Oncology. 43:375-375. 2025
- The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.. Journal of Clinical Oncology. 43. 2025
- Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting A regional cohort analysis.. Journal of the Canadian Urological Association. 19:17-24. 2025
- Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.. International Journal of Radiation Oncology Biology Physics. 120:1461. 2024
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer.. Current Oncology. 31:7226-7243. 2024
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.. Current Oncology. 31:6536-6567. 2024
- Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.. New England Journal of Medicine. 391:1413-1425. 2024
- Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 120:S54-S55. 2024
- Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase II Randomized Trial (NCT03380806). International Journal of Radiation Oncology Biology Physics. 120:S126-S127. 2024
- 124 Phase II Randomized Trial of Optimal Recurrence-Directed Therapy (RDT) Without or with Androgen-Deprivation Therapy (ADT) in Radio-Recurrent Oligo-Metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC): The OCOG-Rational-PCS Trial. Radiotherapy and Oncology. 198:s54-s55. 2024
- 23 Stereotactic Body Versus Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for High-Risk Prostate Cancer (HR-PC); Early Results of PBS: A Phase II Randomized Trial (NCT03380806). Radiotherapy and Oncology. 198:s13-s14. 2024
- Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology. 42:2377-2381. 2024
- Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics. 119:832-837. 2024
- Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. The Lancet. 403:2405-2415. 2024
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. The Lancet. 403:2416-2425. 2024
- Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers. Prostate. 84:193-202. 2024
- Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.. Journal of Clinical Oncology. 42:320-320. 2024
- Characterizing Hematological Changes Following Repeated Exposure to Non-Targeted Low-Dose Ionizing Radiation in Prostate Cancer Patients.. Dose-Response. 22:15593258241276120. 2024
- Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). International Journal of Radiation Oncology Biology Physics. 117:e434-e434. 2023
- Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics. 117:370-377. 2023
- Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 117:S3-S4. 2023
- 114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres. Radiotherapy and Oncology. 186:S53-S53. 2023
- 147 Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). Radiotherapy and Oncology. 186:S67-S67. 2023
- Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. New England Journal of Medicine. 389:612-619. 2023
- Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. Journal of Clinical Oncology. 41:3909-3916. 2023
- Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 116:770-778. 2023
- Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. International Journal of Radiation Oncology Biology Physics. 116:39-49. 2023
- Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.. Journal of Clinical Oncology. 41:363-363. 2023
- Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis.. Journal of Clinical Oncology. 41:45-45. 2023
- Patterns of failure with 18F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.. Journal of Clinical Oncology. 41:309-309. 2023
- Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial. Advances in Radiation Oncology. 8:101066-101066. 2023
- Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 23:1308-1320. 2022
-
Salvage radiotherapy following
HiFU : An institutional series and literature review. Journal of Medical Imaging and Radiation Oncology. 66:847-852. 2022 - LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).. Journal of Clinical Oncology. 40:LBA501-LBA501. 2022
- A systematic review of axillary nodal irradiation for the management of the axilla in patients with early-stage breast cancer. Surgical Oncology. 42:101754-101754. 2022
- Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO clinical cancer informatics. 6:e2100188. 2022
- The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments. Clinical Genitourinary Cancer. 20:e25-e38. 2022
- 151: Prostate SBRT Boost Radiotherapy (PBS Trial): A Randomized Phase II Trial of SBRT Versus Conventionally-Fractionated Radiotherapy Boost Following Pelvic Radiotherapy in High-Risk Prostate Cancer. Radiotherapy and Oncology. 163:S64-S64. 2021
- Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. Journal of Clinical Oncology. 39:3056-3082. 2021
- Abstract 2528: Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415. Cancer Research. 81:2528-2528. 2021
- Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS ONE. 16:e0249123-e0249123. 2021
- A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). Clinical Genitourinary Cancer. 18:e410-e415. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:123-130. 2020
- A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415.. Journal of Clinical Oncology. 38:55-55. 2020
- Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology. 22:437-437. 2020
- External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. The Lancet. 394:2165-2172. 2019
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. The Lancet Oncology. 20:1531-1543. 2019
- 158 Impact of Pelvic Intensity-Modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. Radiotherapy and Oncology. 139:S68-S68. 2019
- Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Radiotherapy and Oncology. 135:19-24. 2019
- Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. JAMA Oncology. 5:664-664. 2019
- Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 102:287-295. 2018
- Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer. JAMA network open. 1:e182081-e182081. 2018
- Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. International Journal of Radiation Oncology Biology Physics. 99:90-93. 2017
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology. 35:1884-1890. 2017
- Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology. 34:2325-2332. 2016
- The Technique, Resources and Costs of Stereotactic Body Radiotherapy of Prostate Cancer. Technology in Cancer Research and Treatment. 15:171-178. 2016
- Biological Response of Positron Emission Tomography Scan Exposure and Adaptive Response in Humans. Dose-Response. 13:155932581561190-155932581561190. 2015
- 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. British Journal of Cancer. 112:1737-1743. 2015
- Locoregional Therapy of Locally Advanced Breast Cancer: A Clinical Practice Guideline. Current Oncology. 22:54-66. 2015
- Long-term Survival in a Patient with Metastatic Spinal Cord Compression from a Prostate Cancer with Ultra-high PSA: Case Report and Review of the Literature. Cureus. 7:e242. 2015
- Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. Practical Radiation Oncology. 4:187-191. 2014
- Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer. Journal of Clinical Oncology. 31:3758-3763. 2013
- Systematic review: conservative treatments for secondary lymphedema. BMC Cancer. 12:6. 2012
- Intensity-modulated Radiotherapy in the Treatment of Breast Cancer. Clinical Oncology. 24:488-498. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 30:6049-6049. 2012
- Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology. 6:144. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 29:7018-7018. 2011
- Conservative and dietary interventions for cancer‐related lymphedema. Cancer. 117:1136-1148. 2011
- In Reply to Dr. Azria et al.. International Journal of Radiation Oncology Biology Physics. 75:1275-1276. 2009
- Radiation-Induced Lymphocyte Apoptosis to Predict Radiation Therapy Late Toxicity in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics. 74:1424-1430. 2009
- Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Research and Treatment. 110:337-342. 2008
- Individual Radiosensitivity and its Relevance to Health Physics. Dose-Response. 5:dose-response.0. 2007
- Current issues in the management of lymphedema in breast cancer patients.. The Journal of Supportive Oncology. 4:392-393. 2006
- Cross-Border Referral for Early Breast Cancer: An Analysis of Radiation Fractionation Patterns. Current Oncology. 13:124-129. 2006
- The Importance of Reporting Patient Recruitment Details in Phase III Trials. Journal of Clinical Oncology. 24:843-845. 2006
- 59 Radiation — Induced apoptosis of lymphocytes to predict normal tissue late toxicity from radiotherapy. Radiotherapy and Oncology. 76:S18-S18. 2005
- Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: a meta-analysis. British Journal of Radiology. 78:777-782. 2005
- Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Journal of Clinical Oncology. 23:1192-1199. 2005
- A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics. 60:S448-S448. 2004
- Arm lymphedema in breast cancer patients: Is it always related to treatment. International Journal of Radiation Oncology Biology Physics. 60:S402-S402. 2004
- BASELINE STAGING OF NEWLY DIAGNOSED PROSTATE CANCER: A SUMMARY OF THE LITERATURE. Investigative Urology. 171:2122-2127. 2004
- Unforeseen complication of brachytherapy. CANADIAN MEDICAL ASSOCIATION JOURNAL. 170:1209-1210. 2004